**Core tip:** Long-term exposure to bioincompatible peritoneal dialysis (PD) solutions frequently results in peritoneal fibrosis and ultrafiltration failure, which limits the life-long use of PD therapy. Beyond uremia *per se*, oxidative stress (OS) also results from chronic exposure to high glucose load, glucose degradation products, advanced glycation end products, and hypertonic stress in PD patients. Therapy targeting the cannabinoid signaling pathway has been reported in several chronic inflammatory diseases with elevated OS. In this article, we review the interaction among the cannabinoid system, inflammation, and OS, through which the health-care professionals ultimately aim to prolong the peritoneal survival of PD patients.

REVIEW ARTICLE
==============

As chronic kidney disease progresses to end-stage renal disease, uremia ensues requiring the use of long-term dialysis therapy. Both uremia and dialysis give rise to elevated oxidative stress (OS)\[[@B1]-[@B4]\], which is detrimental to the patients' health. A recent survey indicated that approximately 11% of dialysis patients undergo peritoneal dialysis (PD) therapy worldwide, estimating to be more than 272000 patients with an 8% annual growth rate globally\[[@B5]\]. Beyond uremia *per se*, PD patients are at an increased risk of inflammation and OS, both systemically and locally, because of the chronic exposure to high glucose load\[[@B6]-[@B15]\], advanced glycosylated end products (AGEs)\[[@B16]-[@B18]\], glucose degradation products (GDPs)\[[@B18]-[@B21]\], and hypertonic stress\[[@B9],[@B22]-[@B24]\]. After long-term exposure to various GDPs and AGEs, mesothelial cells of PD patients undergo a de-differentiation process, followed by peritoneal fibrosis and ultrafiltration failure\[[@B25]-[@B29]\]. In a large peritoneal biopsy study, peritoneal tissue samples from 212 subjects including healthy controls, hemodialysis and PD patients were examined. They found that peritoneal fibrosis was absent in normal individuals but was present in 28% of samples from hemodialysis patients and up to 56% of biopsies from PD patients\[[@B30]\]. Although whether a uremia-induced chronic inflammation status causes OS or OS leads to a proinflammatory process in uremic patients remains uncertain\[[@B1],[@B4],[@B31]\], therapeutic strategies for peritoneal damage targeting OS have been reported, such as antioxidants\[[@B12],[@B18],[@B32],[@B33]\], scavenging agents for reactive oxygen species (ROS)\[[@B34]-[@B36]\], the trace element selenium\[[@B37]\], and gaseous mediators\[[@B38],[@B39]\].

Cannabinoid (CB) signaling has also been reported to be effective in treating a variety of disease entities with elevated OS, including diabetic macrovascular and microvascular complications\[[@B40]-[@B50]\], cardiomyopathies\[[@B51]-[@B57]\], liver injury and fibrosis\[[@B58]-[@B64]\], cholangiopathies\[[@B65]\], colitis\[[@B66],[@B67]\], drug nephrotoxicity\[[@B68],[@B69]\], and autoimmune diseases\[[@B70]\] (Table [1](#T1){ref-type="table"}). Since the peritoneum of long-term PD patients is under a chronic pro-inflammatory status, it is possible that the CB receptor (CBR) signaling system may be inappropriately modulated. In this article, we reviewed the sources and influence of OS in PD patients, and the therapeutic rationale and mechanisms of targeting the CB signaling system to reduce OS.

###### 

Summary of cannabinoid signaling on modulation of diseases with increased oxidative stress

  **Disease**                                     **Species**           **Disease model**   **Ref**.
  ----------------------------------------------- --------------------- ------------------- ---------------------------------
  Diabetes mellitus                                                                         
  Microvascular complications                                                               
  Nephropathy                                     Mouse                 *In vivo*           \[[@B49],[@B50]\]
  Retinopathy                                     Mouse, rat            *In vivo*           \[[@B43],[@B44]\]
  Neuropathy                                      Mouse, rat            *In vivo*           \[[@B45]-[@B47]\]
  Macrovascular complications                     Mouse, rat            *In vivo*           \[[@B40],[@B41]\]
  Cardiomyopathy                                                                            
  Diabetic cardiomyopathy                         Mouse                 *In vivo*           \[[@B57]\]
                                                  Human cardiomyocyte   *In vitro*          \[[@B57]\]
  Myocardial ischemia/reperfusion                 Mouse                 *In vivo*           \[[@B51],[@B53],[@B54]\]
  Ageing-related cardiomyopathy                   Mouse                 *In vivo*           \[[@B55]\]
  Doxorubicin-induced cardiomyopathy              Mouse                 *In vivo*           \[[@B52],[@B56]\]
                                                  Human cardiomyocyte   *In vitro*          \[[@B56]\]
                                                  Rat cardiomyocyte     *In vitro*          \[[@B52]\]
  Cisplatin nephropathy                           Mouse                 *In vivo*           \[[@B68],[@B69]\]
  Liver injury/fibrosis                                                                     
  Ischemia/reperfusion hepatocyte injury          Mouse                 *In vivo*           \[[@B59]\]
  CCl~4~-induced hepatocyte injury                Mouse                 *In vivo*           \[[@B59]\]
  Alcoholic liver fibrosis                        Mouse                 *In vivo*           \[[@B62]\]
  Fibrotic activation of hepatic stellate cells   Human, rat, mouse     *In vitro*          \[[@B58],[@B60],[@B63],[@B64]\]
  Biliary diseases                                                                          
  Cholangiopathies                                Mouse                 *In vivo*           \[[@B65]\]
                                                  Mouse cholangiocyte   *In vitro*          \[[@B65]\]
  Enteric diseases                                                                          
  Inflammatory bowel disease                      Mouse                 *In vivo*           \[[@B66]\]
  Colitis                                         Mouse                 *In vivo*           \[[@B67]\]
  Autoimmune systemic sclerosis                   Mouse                 *In vivo*           \[[@B70]\]

HIGH GLUCOSE AND GDP INCREASE OS
================================

Uremia *per se* and dialysis therapy both lead to a pro-oxidant status, which can lead to increased OS in patients receiving hemodialysis or PD therapy\[[@B1]-[@B4]\]. In particular, PD patients are exposed to hypertonic glucose solution on a long-term basis, which is not only toxic to mesothelial cells\[[@B6],[@B71]\] but also promotes immune cell apoptosis\[[@B72]\]. Moreover, the high-temperature sterilization process produces GDPs such as methylglyoxal (MGO), acetaldehyde, formaldehyde, and 3-deoxyglucosone in PD dialysate\[[@B73]-[@B76]\]. GDPs possess strong oxidative properties and toxicity, and can induce AGEs\[[@B77]\]. In addition, it has been demonstrated that MGO, a key GDP, in PD dialysates inhibits the insulin signaling pathway, resulting in increased endogenous ROS production and subsequent cell injury\[[@B78]\]. Furthermore, 2-33 μmol/L of MGO has been reported to be present in commercial glucose-based PD fluids\[[@B79],[@B80]\].

After long-term exposure to various GDPs and AGEs, mesothelial cells undergo a de-differentiation process and peritoneal fibrosis ensues\[[@B25]-[@B29]\]. Furthermore, these sites of chronic inflammatory have been associated with progressive peritoneal angiogenesis\[[@B29],[@B81]-[@B83]\], and finally a reduction in the efficacy of PD. However, therapeutic strategies for these pathogenic processes have not been fully developed\[[@B81]\], and so some PD patients still develop peritoneal fibrosis or even encapsulating peritoneal sclerosis, a disastrous and highly fatal condition.

Low GDP PD dialysates can prevent peritoneal injury by PD-induced OS. However, the relatively high cost limits their full implementation. Moreover, even though the concentration of GDPs in the new generation of PD dialysates is low, it still exists\[[@B84]-[@B86]\]. Meanwhile, as long as the PD dialysate is glucose-based, glucose load *per se* results in ROS production\[[@B6]-[@B15]\]. Fortunately, therapies reducing peritoneal OS are under investigation, and include antioxidants\[[@B12],[@B18],[@B32],[@B33]\], ROS scavengers\[[@B34]-[@B36]\], selenium\[[@B37]\], and gaseous mediators\[[@B38],[@B39]\] (Figure [1](#F1){ref-type="fig"}).

![Peritoneal dialysis-induced oxidative stress and peritoneal fibrosis. PD: Peritoneal dialysis; GDPs: Glucose degradation products; EMT: Epithelial-mesenchymal transition; ROS: Reactive oxygen species.](WJN-6-111-g001){#F1}

HYPERTONIC DIALYSATE-INDUCED OSMOTIC STRESS AND OXIDATIVE INJURY
================================================================

In addition to low GDP PD dialysates, non-glucose-based PD dialysates such as icodextrin are free of GDPs and have been shown to be beneficial in fluid control and small solute clearance\[[@B87]\]. It has also been reported that peritoneal OS is reduced when using icodextrin compared with conventional PD dialysates\[[@B88]\].

However, other studies have reported conflicting results in that the osmotic stress, a type of stress resulted from hypertonic PD dialysate exposure, leads to oxidative DNA damage of peritoneal mesothelial cells through lipid peroxidation. Such peritoneal oxidative injury may then lead to mesothelial cell death either through apoptosis or necrosis\[[@B9],[@B22]-[@B24]\]. Therefore, persistent efforts are warranted to develop an optimal solution.

THE CANNABINOID SIGNALING PATHWAY AND ITS MOLECULAR MECHANISMS ON INFLAMMATION AND FIBROSIS
===========================================================================================

Our recent study suggested that using CBR ligands as an additive in PD dialysate may be a promising solution to treat dialysis-induced peritoneal inflammation\[[@B89]\]. There are two subtypes of CBRs, type 1 CB receptor (CB~1~R) and type 2 CB receptor (CB~2~R). The former mainly exists in the brain and regulates inhibitory neurotransmitters on neurons through the psychoactive drug cannabis or endocannabinoids such as anandamide. Nevertheless, it has recently been found that CB~1~R also exists in tissues other than that of the central nervous system, and that its function varies in different organs\[[@B73]\]. CB~1~R antagonists and CB~2~R agonists have been shown to decrease inflammation and OS\[[@B48]\], and previous studies have also shown that CBR plays an important role in liver fibrogenesis\[[@B90]-[@B94]\]. Moreover, hepatic fibrosis can be rescued by knockout of the CB~1~R gene or by administration of the CB~1~R antagonist\[[@B93],[@B95],[@B96]\]. In contrast, CB~2~R is located on immune cells and modulates cytokine release\[[@B97],[@B98]\]. Recent studies have shown that the activation of CB~2~R ameliorates liver fibrogenesis through inhibiting myofibroblast cell proliferation\[[@B92],[@B99]\]. Furthermore, CBR ligands such as cannabidiol have been proven to be well-tolerated without adverse effects when administered to humans on a long-term basis\[[@B48]\].

Only a few studies have been published on pharmacological modulation targeting peritoneal inflammation and fibrogenesis using CBR ligands\[[@B100]\]. Our recent study indicated that the pharmacological effects of CBR ligands against dialysate-induced peritoneal fibrosis may involve a diverse signaling system including the TGF-β1-PI3K pathway\[[@B89]\], and that this offers a promising therapeutic strategy for the prevention of peritoneal fibrosis in patients receiving long-term PD. Therefore, we suggest that CBR signaling might play an important role in the pathogenesis of dialysis-induced peritoneal inflammation and ROS production, which required further studies.

CELLULAR SOURCES OF REACTIVE OXYGEN SPECIES IN PD-INDUCED FIBROSIS
==================================================================

*In vitro* data showed that, upon GDP and AGE exposure during PD, cellular OS of human peritoneal mesothelial cells were induced through activation of protein kinase C, nicotinamide adenine dinucleotide phosphate oxidase, and mitochondrial metabolism. In turn, the generated ROS upregulate fibronectin expression by mesothelial cells\[[@B7]\]. An *in vivo* study demonstrated 8-hydroxy-2'-deoxyguanosine (8-OHdG)-positive cells, indicating cells with increased OS, were observed throughout the fibrotic peritoneal tissue. Further immunofluorescent analysis revealed that 8-OHdG-positive cells also co-stained with mesothelin (mesothelial cells), CD68 (macrophages), CD31 (vascular endothelial cells), and α-smooth muscle actin (fibroblasts)\[[@B34]\], suggesting that OS was also increased in cells other than mesothelial cells. However, whether these fibroblasts with increased cellular OS were derived from an epithelial-mesenchymal transition (EMT)-like process of mesothelial cells is unknown.

As aforementioned, it has been reported that CB~2~R is located on immune cells and modulates cytokine release\[[@B97],[@B98]\]. The CB~2~R expression of human lymphocytes was downregulated by TGF-β stimulation\[[@B101]\], which was not seen in human mesothelial cells\[[@B89]\]. These findings suggest that TGF-β1 might have different physiological function in different cell types. Meanwhile, CB~2~R activation might exert its anti-fibrotic effects not directly to cells undergoing fibrotic change but indirectly through modulating the immune cells. Such interaction among different types of cells underlines the pathophysiological role of CBR signaling pathway in uremic and/or dialysis injuries, which is partly supported by a recent study showing that systemic administration of interleukin-10, an anti-inflammatory cytokines secreted by M2 macrophages, significantly reduced fibrous peritoneal thickening\[[@B102]\]. Therefore, current evidence indicates that beyond mesothelial cells, macrophages and vascular endothelial cells also contribute to ROS production during PD-induced peritoneal fibrosis.

THERAPEUTIC POTENTIAL OF CANNABINOID SIGNALING ON PD-INDUCED OS AND INFLAMMATION
================================================================================

It has been reported that modulating the CB signaling system is beneficial in treating various diseases resulting from increased OS including diabetic macrovascular and microvascular complications\[[@B41]-[@B43],[@B48],[@B57]\], cardiomyopathies\[[@B51],[@B55]-[@B57]\], liver injury and fibrosis\[[@B58],[@B60]-[@B64],[@B103]\], cholangiopathies\[[@B65]\], colitis\[[@B66],[@B67]\], drug nephrotoxicity\[[@B68],[@B69]\], and autoimmune diseases\[[@B70]\]. At present, evidences of the therapeutic benefit of CBR ligands on peritoneal OS are lacking and deserve investigations.

Furthermore, recent studies have also shown significant anti-fibrogenic effects of CBR ligands in the liver\[[@B91]-[@B93],[@B95],[@B96],[@B99]\]. However, the effects of CBR ligands on peritoneal tissue have rarely been studied, with only one recent study reporting that the CB~2~R agonist reduced the number of peritoneal macrophages in a murine peritonitis model induced by thioglycollate, an AGE derivative\[[@B104]\]. Furthermore, we recently demonstrated that both the selective CB~1~R antagonist (AM281) and the selective CB~2~R agonist (AM1241) were able to ameliorate MGO-induced peritoneal fibrosis *in vivo*, indicating that pharmacological modulation of CBR may be a feasible approach to optimize the biocompatibility of peritoneal dialysis fluid. However, ACEA, a CB~1~R agonist, has been shown to have an opposite effect to AM281 with regards type I collagen expression in cultured mesothelial cells, indicating specific anti-fibrogenic activity of the CB~1~R antagonist\[[@B89]\].

During peritoneal fibrosis, mesothelial cells undergo a process of myofibroblastic conversion. This is a complex process which has been reported to be associated with increased levels of TGF-β1, leptin, metalloproteinase-2, vascular endothelial growth factor, Snail, and the receptor for advanced glycosylated end products\[[@B79],[@B105],[@B106]\]. TGF-β1 has long been known to play crucial roles in the fibrogenic process of the peritoneum\[[@B107],[@B108]\]. A previous study demonstrated that a high glucose load stimulates the production of TGF-β1 in peritoneal mesothelial cells\[[@B109]\]. Moreover, AGEs have been shown to increase the expression of TGF-β1, contribute to the development of sub-mesothelial fibrosis\[[@B110]\], and significantly contribute to increases in peritoneal OS. Meanwhile, our recent study showed that such EMT-like processes can be attenuated by the selective CB~1~R antagonist, AM281\[[@B89]\]. It is quite possible that OS is involved in the CBR-related pharmacological effects against peritoneal fibrosis. However, the exact pathogenic mechanisms between the CBR signaling pathway and uremic and/or dialysis injuries remain largely unknown.

CONCLUSION
==========

Compared with hemodialysis patients, the chronic use of PD dialysate exposes PD patients to additional OS. The influence of such OS on the patients' health can be both systemic and local, leading to cardiovascular diseases and peritoneal fibrosis, respectively. It has been shown that OS plays a critical role in the pathogenesis of chronic inflammatory diseases, and therefore targeting the CB signaling system may offer a potential therapeutic strategy to reduce dialysis-induced peritoneal fibrosis and eventually to prolong the peritoneal survival of PD patients.
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